Radium Ra-223
- Generic Name
- Radium Ra-223
- Drug Type
- Small Molecule
- Chemical Formula
- Ra
- CAS Number
- 15623-45-7
- Unique Ingredient Identifier
- 8BR2SOL3L1
- Background
Radium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
- Conditions
- Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Malignant Neoplasm in the Bone
- Interventions
- Procedure: PSMA Positron Emission Tomography (PET) Scan
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 54
- Registration Number
- NCT05924672
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- GenesisCare USA
- Registration Number
- NCT05771896
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate CancerMCRPCProstate Cancer
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 36
- Registration Number
- NCT05383079
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
- Conditions
- Metastatic Castration-resistant Prostate CancerBone Metastases
- Interventions
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 8
- Registration Number
- NCT05301062
- Locations
- 🇨🇳
Many locations, Multiple Locations, China
Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223
- Conditions
- Castrate Resistant Prostate CancerBone Metastases
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 122
- Registration Number
- NCT04995614
- Locations
- 🇳🇱
Catharina ziekenhuis, Eindhoven, Netherlands
🇳🇱Canisius-Wilhelmina ziekenhuis, Nijmegen, Netherlands
🇳🇱Rijnstate ziekenhuis, Arnhem, Netherlands
Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH
- Conditions
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Interventions
- Drug: NAH therapy
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 696
- Registration Number
- NCT04597125
- Locations
- 🇫🇷
Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-les-Nancy, France
🇫🇷Gustave Roussy - Departement Oncologie-Radiotherapie, Villejuif Cedex, France
🇦🇺Specialist Services Medical Group, Castle Hill, New South Wales, Australia
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
- Conditions
- Bone Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 46
- Registration Number
- NCT04521361
- Locations
- 🇫🇷
Institut Claudius Regaud - iUCT Oncopole, Toulouse Cedex 9, France
🇮🇱Rambam Health Corporation, Haifa, Israel
🇦🇹Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1180
- Registration Number
- NCT04516161
- Locations
- 🇺🇸
Bayer Flatiron Xofigo Registry database, Whippany, New Jersey, United States
Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4301
- Registration Number
- NCT04281147
- Locations
- 🇨🇦
Multiple Locations, Multiple Locations, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.